AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 16859225
Drug: Neomycin-polymyxin solution
RxNorm normalized name: neomycin / polymyxin B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin-polymyxin solution
Trial: 12590375
Drug: Clonidine 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.15 mg/day
Trial: 7572582
Drug: Mibefradil 150
RxNorm normalized name: mibefradil
DrugBank: Mibefradil (DB01388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mibefradil 150 mg
Trial: 8408529
Drug: RU486 (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU486 (600 mg)
Trial: 8408529
Drug: RU486 (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU486 (3 x 25 mg)
Trial: 8408529
Drug: RU486 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RU486 (25 mg)
Trial: 15722780
Drug: Drug therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapies for complex regional pain syndrome
Trial: 15722780
Drug: Pharmacotherapy coupled
RxNorm normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy coupled with functional restoration and interdisciplinary approach
Trial: 12229131
Drug: Morphine (IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (IV PCA) alone (2 mg bolus, 10-minute lock-out interval, 10 mg/hour limit for 48 hours)
Trial: 10102019
Drug: Conventional cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cranial irradiation (CRT) regimen (L874A and I874A) - 18-Gy CRT plus 3 doses of intrathecal (i.t.) MTX
Trial: 10102019
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) regimen without CRT (L874B and I874B) - 3 courses of HDMTX at 2 g/m2 plus 13 doses of ITMTX or 4 courses of HDMTX at 4.5 g/m2 plus 1 dose of ITMTX
Trial: 10102019
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (HDMTX) regimen without CRT (I874B)
Trial: 10102019
Drug: Intensive systemic
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive systemic chemotherapy with extended i.t. injections of MTX plus cytarabine
Trial: 10102019
Drug: Cranial irradiation
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranial irradiation (18-Gy or 24-Gy) with intensive systemic chemotherapy
Trial: 2265371
Drug: HPP 3
RxNorm normalized name: 4-HPP
DrugBank: Allopurinol (DB00437)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HPP 3 x 300 mg po, days 1-5, 5-FU 800 mg/m2 push iv, days 3-5 and DDP 50 mg/m2 d6
Trial: 2265371
Drug: 5-FU alone
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU alone 500 mg/m2 push iv days 1-5
Trial: 7004247
Drug: Cinnarizine in
RxNorm normalized name: Product containing cinnarizine in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine in combination with phenylpropanolamine
Trial: 28248418
Drug: Customized behavioral
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized behavioral urinary incontinence treatments combined with physical activity (150 minutes of weekly walking and twice weekly strength training classes)
Trial: 28248418
Drug: Customized behavioral
RxNorm normalized name: sulfur
DrugBank: Octasulfur (DB09353)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Customized behavioral urinary incontinence treatments combined with physical activity
Trial: 25271779
Drug: Group cognitive-behavioral
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive-behavioral therapy (22 sessions)
Trial: 25271779
Drug: Group supportive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group supportive therapy (control, 22 sessions)
Trial: 17596103
Drug: Vildagliptin 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 25 mg and 100 mg
Trial: 14872477
Drug: Escalating doses
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escalating doses of IM methotrexate up to 45 mg/week
Trial: 14872477
Drug: 15 mg/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/week IM methotrexate with monthly placebo escalation
Trial: 11163032
Drug: Allopurinol (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol (administered with pre-medication)
Trial: 31180297
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta treatment to a hemoglobin target level of 11.5 to 13.5 g/dL
Trial: 31180297
Drug: Epoetin beta
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Epoetin beta treatment
Trial: 16681436
Drug: Adrenocorticotrophic hormone
RxNorm normalized name: Adrenocorticotrophic hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenocorticotrophic hormone (ACTH)(1‐24) 1 mg i.m. daily for 4 days
Trial: 16681436
Drug: Cortisol 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cortisol 50 mg i.m. t.i.d. for 4 days
Trial: 9771317
Drug: Extubation while
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extubation while sedated (propofol 1‐3 mg kg‐1 h‐1)
Trial: 3063797
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg sublingually
Trial: 21311184
Drug: Oral mycophenolate
RxNorm normalized name: mycophenolate
DrugBank: Mycophenolic acid (DB01024)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mycophenolate mofetil (MMF) 1.0 g/day (1.5 g/day for patients >70 kg)
Trial: 21311184
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (IVC) 1.0 g per pulse (0.8 g for patients <50 kg)
Trial: 21121175
Drug: Amantadine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine (100 mg)
Trial: 2570799
Drug: terfenadine, 60
RxNorm normalized name: Terfenadine, 60 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: terfenadine, 60 mg
Trial: 8201490
Drug: chlorpheniramine, 4
RxNorm normalized name: Chlorpheniramine, 4 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlorpheniramine, 4 mg
Trial: 3276299
Drug: Controlled-release carbidopa-levodopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbidopa-levodopa (CR-2 or CR-3)
Trial: 3276299
Drug: Standard carbidopa-levodopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard carbidopa-levodopa (Sinemet, 25 mg/100 mg)
Trial: 21167330
Drug: Multi-component physical
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-component physical activity intervention including daily physical education with at least 10 min of jumping or strength training exercises of various intensities.
Trial: 1519829
Drug: Control solutions
RxNorm normalized name: Accu-Chek Comfort Curve Control Solutions
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control solutions
Trial: 12572377
Drug: Yishen Jiedu
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yishen Jiedu Recipe (YSJDR) in addition to low-protein diet and blood pressure controlling therapy
Trial: 12572377
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet and blood pressure controlling therapy only
Trial: 26673391
Drug: H7N9 live
RxNorm normalized name: Typhoid Vaccine Live
DrugBank: Typhoid Vaccine Live (DB11050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H7N9 live attenuated influenza vaccine
Trial: 20307166
Drug: Smoking intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking intervention (eight-session individually administered trial)
Trial: 18584479
Drug: Soy extract
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy extract supplementation (3 Evestrel capsules, providing a total of 112.5 mg isoflavones aglycone eq/day) for 3 days before prostate surgery
Trial: 16875160
Drug: PGE1 (Prostavasin)
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE1 (Prostavasin) infusion at a dose of 0.02 mg/kg b.m./min
Trial: 12800417
Drug: Astragalus Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astragalus Injection (AI) 30 ml (equivalent to 60 g crude drug) administered intravenously once a day for 20 days
Trial: 12800417
Drug: Nitroglycerine injection
RxNorm normalized name: nitroglycerin Injection
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerine injection 10 mg administered intravenously once a day for 20 days (Control group)
Trial: 8872850
Drug: Co-amilozide (thiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-amilozide (thiazide diuretic)
Trial: 8157550
Drug: Ciprofloxacin 400
RxNorm normalized name: ciprofloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 400 mg i.v.
Trial: 1510426
Drug: Ciprofloxacin oral
RxNorm normalized name: ciprofloxacin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin oral doses (500 mg and 750 mg)
Trial: 1510426
Drug: Ciprofloxacin i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin i.v. dosing
Trial: 6682776
Drug: Cis-diamminedichloroplatinum (II)
RxNorm normalized name: CIS-DIAMMINEDICHLOROPLATINUM
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cis-diamminedichloroplatinum (II) (CDDP) at various doses (20 mg/m2, 25-50 mg/m2, 70-120 mg/m2)
Trial: 6682776
Drug: Rapid infusion
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid infusion of a single high dose of CDDP
Trial: 6682776
Drug: Daily low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily low dose of CDDP for 5 days
Trial: 6682776
Drug: Single low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single low dose of CDDP
Trial: 26199465
Drug: Intranasal Dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Dexmedetomidine (DEX)
Trial: 30450972
Drug: Dry heat
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dry heat treatment (fluidotherapy)
Trial: 27656053
Drug: Alprazolam and
RxNorm normalized name: Alprazolam and propranolol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam and Diclofenac Potassium (pre-medication)
Trial: 27656053
Drug: Gow-Gates technique
RxNorm normalized name: zinc pyrithione
DrugBank: Pyrithione (DB06815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gow-Gates technique with pre-medication
Trial: 27656053
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without pre-medication)
Trial: 24864502
Drug: Solcoseryl Eye
RxNorm normalized name: Solcoseryl
DrugBank: Solcoseryl (DB15794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solcoseryl Eye Gel
Trial: 20057344
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone acetonide (IVTA) injection plus panretinal photocoagulation (PRP) and macular photocoagulation (MPC)
Trial: 16123680
Drug: pegylated interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pegylated interferon alpha‐2b 1.5 microg/kg/wk and ribavirin 800‐1200 mg/d for 24 weeks
Trial: 12469988
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg and 10 mg once daily)
Trial: 7579555
Drug: Tropisetron, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron, 5 mg o.d. plus dexamethasone, 12 mg i.v. on day 1 followed by 4 mg orally b.i.d. on days 2‐5
Trial: 7579555
Drug: Tropisetron, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tropisetron, 5 mg o.d.
Trial: 6106611
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 250 mg
Trial: 6106611
Drug: Chloral hydrate
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloral hydrate 500 mg
Trial: 27321790
Drug: Levosimendan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levosimendan (10 µg/kg bolus followed by infusion at a rate of 0.1 µg/kg/min for 24 hours)
Trial: 27321790
Drug: Milrinone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milrinone (50 µg/kg bolus followed by infusion at a rate of 0.5 µg/kg/min for 24 hours)
Trial: 11977638
Drug: Amifostin (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostin (treatment group A)
Trial: 7268356
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg sulfinpyrazone with sodium load
Trial: 30635007
Drug: TEAS combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TEAS combined with opioid drugs
Trial: 30461602
Drug: Intravenous propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous propofol anesthesia
Trial: 27884128
Drug: Oral probiotic
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral probiotic treatment (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 at a dose of 7 × 10^9 colony-forming units one per day until birth)
Trial: 19681775
Drug: Glutamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.5 g/kg/day)
Trial: 18835506
Drug: Isonitrogenous, isocaloric,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isonitrogenous, isocaloric, isovolemic nutritional solution
Trial: 12034156
Drug: Pentoxifylline 400
RxNorm normalized name: pentoxifylline 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg TID in addition to diuretics, digoxin, enalapril and carvedilol
Trial: 12034156
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (diuretics, digoxin, enalapril and carvedilol)
Trial: 9562007
Drug: Alteplase (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alteplase (100 mg 2-h infusion)
Trial: 3204147
Drug: Tamoxifen 30
RxNorm normalized name: tamoxifen 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen 30 mg administered 12 h before hCG injection and 48 h before oocyte capture
Trial: 329406
Drug: 1000 IU
RxNorm normalized name: D 1000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU of calciferol daily for 8 months
Trial: 29752009
Drug: Omega-3 PUFAs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 PUFAs (2 g daily, 8 weeks)
Trial: 25137844
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia (sufentanil combined propofol)
Trial: 25137844
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with intravenous anesthesia (sufentanil, propofol combined with acupuncture)
Trial: 19067708
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% and Vehicle (control)
Trial: 16027437
Drug: Supplementation with
RxNorm normalized name: Similac For Supplementation with Iron Powder for Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplementation with alpha‐tocopherol (400 IU/d) and beta‐carotene (30 mg/d)
Trial: 12004847
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 5‐FU (600 mg/m2 24‐hour infusion for five days, then 600 mg/m2 IV once a week) and IFN (5 MU subcutaneously three times a week for six months)
Trial: 12004847
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of leucovorin (20 mg/m2 rapid intravenous injection) and 5‐FU (425 mg/m2 IV days 1‐5 every 28 days for six cycles)
Trial: 10457120
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg u.i.d.) plus flunisolide (two 25 microg puffs per nostril morning and night)
Trial: 28249612
Drug: Cisplatin chemo‐irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin chemo‐irradiation with SIB-IMRT, escalating total dose to the GTV up to 80.5 Gy. Chemotherapy planned either in the 1st and 5th week (cisplatin 20 mg/m2/d d 1-5 and d 29-33) or weekly (cisplatin 40 mg/m2/d) during RT. RT delivered as SIB with total doses of 80.5 Gy/70.0 Gy/56.0 Gy with 2.3 Gy/2.0 Gy and 1.6 Gy.
Trial: 28249612
Drug: Control arm
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control arm with cisplatin chemo‐irradiation, total doses of 70.0 Gy/56.0 Gy with 2.0 Gy and 1.6 Gy.
Trial: 28249612
Drug: Pre-study with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-study with dose escalation up to 77.0 Gy/70.0 Gy/56.0 Gy with 2.2 Gy/2.0 Gy and 1.6 Gy.
Trial: 24176010
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg R. crenulata extract
Trial: 17309996
Drug: Cross-linked hyaluronic
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross-linked hyaluronic acid injections
Trial: 17309996
Drug: Vehicle (isotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (isotonic sodium chloride) injections
Trial: 15115710
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg every 3 days for 3 injections)
Trial: 9862512
Drug: Interleukin-2 (IL-2)
RxNorm normalized name: Fusion protein comprised of a circularly-permuted interleukin-2 (IL-2) with the extracellular domain of IL-2 receptor alpha
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 (IL-2) alone, 18 x 10(6) IU/m2, 24-hour i.v. infusion cycles, days 1 to 4, for 25 weeks
Trial: 9862512
Drug: Interferon-alpha (IFN)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN) alone, 6 x 10(6) IU/m2, days 1, 3, and 5, weekly for 52 weeks
Trial: 9862512
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IFN and IL-2, same doses as above, for 24 weeks
Trial: 8541104
Drug: Monoclonal Lewis
RxNorm normalized name: sialyl Lewis A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal Lewis Y antibody (100 mg, six doses over 2 weeks)
Trial: 8541104
Drug: Placebo regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo regimen (six infusions of human serum albumin)
Trial: 22850121
Drug: Rifapentine 10
RxNorm normalized name: Rifapentine
DrugBank: Rifapentine (DB01201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rifapentine 10 mg/kg/dose, administered 5 days per week for 8 weeks
Trial: 22850121
Drug: Rifampin 10
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampin 10 mg/kg/dose, administered 5 days per week for 8 weeks
Trial: 19232887
Drug: Polished surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polished surface treatment
Trial: 19232887
Drug: Matte surface
RxNorm normalized name: hepatitis B surface antigen vaccine Injection [Recombivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matte surface treatment
Trial: 19232887
Drug: Polymethyl methacrylate‐coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymethyl methacrylate‐coated surface treatment
Trial: 16300701
Drug: Injection triamcinolone
RxNorm normalized name: triamcinolone Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection triamcinolone acetonide with lignocaine
Trial: 16300701
Drug: Injection lignocaine
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection lignocaine alone
Trial: 8542460
Drug: Orally administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered sodium cromoglycate
Trial: 2611040
Drug: Immunotherapy (corynebacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (corynebacterium parvum s.c. around the scar 2 weeks after mastectomy) in node negative patients
Trial: 2611040
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of immunotherapy and CMF in node positive patients
Trial: 2611040
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further adjuvant therapy in node positive patients
Trial: 2611040
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further adjuvant therapy in node negative patients